Stablepharma Limited

Stablepharma Ltd is an innovative biopharmaceutical company developing a range of next generation fridge-free vaccine products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults and children most at risk of death and disability caused by vaccine preventable diseases. StablevaX is an adaptable fridge-free technology which offers an extended shelf-life, reduces vaccine wastage and the CO2 footprint of the cold-chain. The WHO estimate that approximately 50% of all vaccines manufactured are wasted due to failures in the global Cold Chain (distribution and storage of vaccines). Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature. Stablepharma is developing the worlds first fridge-free vaccine, SPVX02 for Tetanus diphtheria, a speciality pharmaceutical product for the prevention of Tetanus and Diphtheria